Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NovaBay Pharma ( (NBY) ) has provided an update.
NovaBay Pharma held its Annual Meeting of Stockholders on October 16, 2025, where several key decisions were made. The stockholders approved a reverse stock split, which will reduce the number of outstanding shares and potentially affect voting rights and future share issuances. Additionally, significant changes in the company’s leadership were announced, with the resignation of several board members and the appointment of Michael Kazley as the new CEO and Chairman. The company also filed a Certificate of Amendment to increase its authorized shares of common stock, while a proposal to increase preferred stock was not approved.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
NovaBay Pharma’s overall stock score reflects significant financial challenges, with declining revenues and negative profit margins being the most impactful factors. While technical indicators show some bullish momentum, the valuation remains unattractive due to unprofitability. Positive corporate events, including a strategic shift and special dividend, provide some optimism for future prospects.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
Average Trading Volume: 7,007,918
Technical Sentiment Signal: Sell
Current Market Cap: $6.25M
See more data about NBY stock on TipRanks’ Stock Analysis page.